Recent Updates
Recently added Catalysts

Immune checkpoint inhibitors or docetaxel

Phase 3

Nonsmall Cell Lung Cancer | Small molecule | Oncology |NovoCure Limited|Last Updated: Mar 18, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment291
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02973789Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)PHASE3 COMPLETED 291 — — Dec 1, 2016Oct 9, 2024Mar 18, 2026124 United States, Austria +16
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Overall Survival of Patients Treated With TTFields + Docetaxel or Immune Checkpoint Inhibitors vs. Docetaxel or Immune Checkpoint Inhibitors Alone (Superiority Analysis)
From date of randomization until the date of death from any cause, assessed up to 12 month after the last participant was enrolled (median duration of follow-up was 10.0 months).
Secondary Endpoints
Overall Survival of Patients Treated With TTFields + Immune Checkpoint Inhibitors vs. Immune Checkpoint Inhibitors Alone (Superiority)
From date of randomization until the date of death from any cause, assessed up to 12 month after the last participant was enrolled (median duration of follow-up was 10.6 months).
Overall Survival of Patients Treated With TTFields + Docetaxel vs. Docetaxel Alone (Superiority Analysis)
From date of randomization until the date of death from any cause, assessed up to 12 month after the last participant was enrolled (median duration of follow-up was 9.7 months).
Overall Survival of Patients Treated With TTFields + Docetaxel Vs. Immune Checkpoint Inhibitors Alone (Non-inferiority Analysis)
From date of randomization until the date of death from any cause, assessed up to 12 month after the last participant was enrolled. (median duration of follow-up was 10.1 months)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
NovoTTF-200TEXPERIMENTALPatients receive TTFields using the NovoTTF-200T device together with immune checkpoint inhibitors or docetaxel
Best Standard of CareACTIVE_COMPARATORPatients receive best standard of care with immune checkpoint inhibitors or docetaxel
Interventions
NameTypeDescription
NovoTTF-200TDEVICEPatients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine. Other Name: TTFields Drug: Immune checkpoint inhibitors or docetaxel Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
Immune checkpoint inhibitors or docetaxelDRUGPatients receive standard of care with Immune checkpoint inhibitors or docetaxel
Unlock Study Design Details
Eligibility Criteria
Age Range22 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites124

Inclusion Criteria: 1. 22 years of age and older (some regional variations to inclusion age exist) 2. Life expectancy of ≥ 3 months 3. Histological diagnosis of squamous or non-squamous, inoperable, metastatic NSCLC 4. Diagnosis of radiological progression while on or after first platinum-based sys...

Countries:United StatesAustriaBelgiumBulgariaCanadaChinaCroatiaCzechiaFranceGermanyHong KongHungaryItalyNetherlandsPolandSerbiaSpainSwitzerland
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMMay 21, 2026NCT02973789TRIAL_REMOVED: changed
MEDIUMMay 21, 2026NCT02973789TRIAL_REMOVED: changed